Autopsy report · NCT02618915

Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

“Sponsor decision; not due to any safety concerns related to DTX101.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 10 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Ultragenyx Pharmaceutical Inc

Sponsor type

Industry

Conditions

Hemophilia B

Interventions

DTX101

Participants

6

Sites

9

Countries

Bulgaria, United Kingdom, United States

Trials that died the same way

• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
  “Sponsor decision, not for safety reasons.” (70% match in meaning)
• A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
  “Not due to safety reasons (sponsor decision).” (70% match in meaning)
• (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
  “Sponsor decision, not related to safety concerns” (69% match in meaning)
• A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts
  “Sponsor decision, not safety related” (69% match in meaning)
• Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
  “This was a sponsor decision and was not a consequence of any safety concern” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.